Get the Stockscreener App
51.59
5.16%
2.53
After Hours:
51.45
-0.14
-0.27%
Moderna Inc stock is traded at $51.59, with a volume of 6.70M.
It is up +5.16% in the last 24 hours and up +9.07% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$49.06
Open:
$49.398
24h Volume:
6.70M
Relative Volume:
0.93
Market Cap:
$20.47B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-6.333
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
+8.45%
1M Performance:
+9.07%
6M Performance:
+102.43%
1Y Performance:
+89.18%
1-Day Range:
$48.94
$51.90
1-Week Range:
$43.90
$51.90
52-Week Range:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
51.59 | 19.47B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
441.74 | 108.72B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
628.73 | 64.89B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
842.27 | 50.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.64 | 39.06B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.69 | 33.16B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna gets good news as it searches for life after Covid - thestreet.com
Why Is Moderna (MRNA) Stock Rocketing Higher Today - TradingView
Broadcom’s Guidance Miss Exposes the Fragility of the AI Trade - Investing.com
[144] Moderna, Inc. SEC Filing - Stock Titan
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Future Challenges - GuruFocus
Moderna Stock: Is MRNA Outperforming the Health Care Sector? - Yahoo Finance
Moderna Inc. stock (US60770K1034): EMA committee backs new RSV vaccine as shares bounce on Nasdaq - AD HOC NEWS
Moderna (MRNA) Climbs 7.5% Ahead of Next Week’s Key Updates - Insider Monkey
Moderna rallies on renewed optimism around its Merck-partnered melanoma vaccine program - Quiver Quantitative
MRNA Stock Quote Price and Forecast - CNN
Moderna (MRNA) CFO exercises 2,475 RSUs, 1,197 shares withheld for taxes - Stock Titan
Moderna (MRNA) CLO converts RSUs into stock while 1,047 shares withheld for taxes - Stock Titan
Moderna (MRNA) president exercises RSUs, reports tax share withholding - Stock Titan
Moderna (NASDAQ:MRNA) Trading 8.1% HigherShould You Buy? - MarketBeat
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion - Investing News Network
HEALTH ROUNDS-Radiation-emitting implant improves outcomes after brain cancer surgery - marketscreener.com
Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026 - Yahoo Finance
Moderna Launches Moderna Direct with “eCommerce Powered by FFF Enterprises™” - Yahoo Finance
Moderna CEPI Ebola Vaccine Work Highlights Broader Infectious Disease Ambitions - Yahoo Finance
Moderna to Present at Upcoming Conference in June 2026 - Investing News Network
MRNA Partners With CEPI to Develop Vaccine for Bundibugyo Ebolavirus - Zacks Investment Research
UBS Lifts Valuation On Moderna, Inc. (MRNA) Ahead of Key Pipeline Catalysts - Insider Monkey
Biotech Movers: Moderna, Iovance, ALHC, SMMT in Focus - Gotrade
ASCO: Moderna’s mRNA-based melanoma vaccine shows ‘encouraging’ 5-year survival - BioSpace
Moderna, Inc. $MRNA Shares Acquired by Lingotto Investment Management LLP - MarketBeat
Moderna and other groups get $60mln to develop Ebola vaccine - ZAWYA
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus - Black Hills Pioneer
Moderna, Inc. $MRNA Holdings Lowered by Geode Capital Management LLC - MarketBeat
AXQ Capital LP Purchases 39,835 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna and other groups get $60 million to develop Ebola vaccine By Reuters - Investing.com
Drugmaker Moderna, other groups get $60 mln to develop Ebola vaccine - Yahoo Finance UK
Why (MRNA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Moderna Tells Fed. Circ. US Must Face COVID Vax Patent Case - Law360
Moderna and other groups get $60 million to develop Ebola vaccine - Reuters
Moderna (MRNA) and Merck (MRK) Report Promising Results for Canc - GuruFocus
Moderna gets $50M investment for Ebola vaccine candidate - Yahoo
Moderna and other groups get US$60 million to develop Ebola vaccine - CP24
Moderna Reports Strong 5-Year Cancer Vaccine Data, Expands CEPI Partnership; Stock Falls - Benzinga
Cambridge drugmaker Moderna joins the Ebola vaccine race - NBC Boston
Moderna joins race for Ebola vaccine as Bundibugyo strain spreads in Africa - The Business Journals
Moderna and CEPI expand collab to include Bundibugyo ebolavirus vaccine - The Pharma Letter
Moderna partners with CEPI on Ebola vaccine efforts amid outbreak in Africa - BioSpace
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting - ACCESS Newswire
Moderna Joins Global Initiative to Advance Vaccine Candidate for Bundibugyo Ebola Virus (MRNA) - Yahoo Finance
Moderna receives $50 million from CEPI for Bundibugyo Ebola vaccine - StreetInsider
Moderna (MRNA) Expands Vaccine Collaboration to Combat Bundibugy - GuruFocus
Moderna partners with global health coalition to develop Bundibugyo Ebola vaccine - Yahoo! Finance Canada
Moderna, Inc. (MRNA) Stock Analysis: Evaluating a Biotech Powerhouse with a -8.46% Potential Downside - DirectorsTalk Interviews
Moderna, Inc. $MRNA Position Reduced by Legal & General Group Plc - MarketBeat
Moderna backs new Ebola vaccine as CEPI commits up to $50M - Stock Titan
CEPI fast-tracks three Bundibugyo ebolavirus vaccine candidates - CEPI
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.89%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):